Navigation Links
Meningococcal-B Vaccine Greatly Reduces The Risk of The Disease

A new study has shown the children and teenagers who had been immunised against epidemic meningococcal B disease are five times less likely to be infected// than those who haven't been vaccinated.

Reports have shown that the biggest mass immunisation campaign that had taken place among the young New Zealanders has resulted in a five-fold reduction in the risk of acquiring Meningococcal B disease. The officials from the Ministry of health have stated that according to the initial results of the study conducted by the Victoria University of Wellington has showed that the children who were not immunised were almost five times more likely to suffer the disease. Stating that this disease has affected nearly 6,000 people since the epidemic began in 1981, they said that this disease has killed 239 people in a 25-year epidemic that has hit the country.

It has been reported that 1-in-5 of the survivors have been left with some degree of disability, that includes hearing loss, brain damage, amputation or scarring. Dr Jane O'Hallahan, the director of the immunisation programme has said that if the current trends continue, then substantial progress will been made towards ending the epidemic by the end of the year, which means it could be ended technically several years before its natural end.

Meningococcal disease is a bacterial infection, which causes severe illnesses including meningitis that is an infection of membranes covering the brain, and septicaemia a serious blood infection. Officials at the ministry have explained hat though anyone is vulnerable to the disease, the biggest risk group would be teenagers and children under 20 yrs of age, and more than half of those in that group are below 5 yrs.


'"/>




Page: 1

Related medicine news :

1. Vaccine to quit smoking?
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Vaccine for Alzheimer’s diseas
4. Health Officials Recommend Flu Vaccine
5. Smallpox Vaccine May Help Fight Cervical Cancer
6. Panacea Biotech To Market Anthrax Vaccine
7. New Prostate Cancer Vaccine Shows Promise
8. Drug Firm Offers to Donate Smallpox Vaccine
9. Vaccine guards against shingles
10. Vaccine for septic conditions
11. A new Vaccine for Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/21/2017)... ... July 21, 2017 , ... ... years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could ... after surgery, though activity levels decline over time. The study, presented today at ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... why concussion rates are on the rise, say researchers presenting their work at ... Toronto, Ontario, Canada. , “The combination of evaluating the patterns of change in ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
(Date:7/20/2017)... NY, July 20, 2017 (PRWEB) , ... ... ... Nastel Technologies, a global provider of enterprise-grade IT operations analytics and application ... arm of one of world’s largest healthcare services providers. , According to ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended ... The adjustable beds used in such facilities are specially designed to accommodate patients with ... support. , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 13, 2017  Centurion Medical Products, a leader in medical product ... fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part ... alleviate patient pain while preventing unneeded emergency department admission due to ...
(Date:7/11/2017)... IRVINE, Calif. , July 11, 2017 Zymo Research Corp., ... new service that can quantify biological aging in a precise manner using ... Dr. Steve Horvath , a professor of human genetics and biostatistics ... Fielding School of Public Health , Zymo Research,s proprietary DNAge ™ ... loci. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: